Date: 2017-10-02
Type of information: Financing round
Company: KSQ Therapeutics (USA - MA)
Investors: Flagship Pioneering (USA - MA) Polaris Partners (USA - MA) ARCH Venture Partners (USA - IL) Alexandria Equities (USA - CA)
Amount: $76 million
Funding type: financing round
Planned used:
- KSQ Therapeutics is a company pioneering high-confidence drug development utilizing a suite of CRISPR-based technologies - including itts proprietary CRISPRomics™ drug discovery engine - that industrialize a high-throughput, systematic way to elucidate the precise function that each human gene plays across a multitude of diseases. Based on this deep and comprehensive approach, KSQ is advancing a pipeline of oncology and immunology drug development programs against novel therapeutic nodes to create a new set of disease-tailored medicines.
- KSQ was founded in 2015 by David Sabatini of the Whitehead Institute and MIT, William Hahn of the Broad Institute and Dana-Farber Cancer Institute, Jonathan Weissman, of UCSF, and Tim Wang, of MIT, along with founding investors Flagship Pioneering and Polaris Partners.
- Since the company’s formation in 2015, KSQ has deployed its CRISPRomics engine to complete the functional assessment of each gene in more than 600 tumor and immune models. The company has compiled new insights in disease biology to identify novel drug targets and new drug combinations designed to elicit maximal impact on disease. This approach has produced KSQ’s initial pipeline of drug development programs, and will serve as a product engine across a wide range of disease areas for the company and future collaborators. KSQ has grown to a team of more than 40 employees.
Others:
- • On October 2, 2017, KSQ Therapeutics announced a $76 million financing round led by Flagship Pioneering; Polaris Partners, ARCH Venture Partners, and Alexandria Equities also participated.
Therapeutic area: Cancer - Oncology - Immunological diseases
Is general: Yes
